<?xml version='1.0' encoding='utf-8'?>
<document id="27245340"><sentence text="Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects."><entity charOffset="54-66" id="DDI-PubMed.27245340.s1.e0" text="Atorvastatin" /><entity charOffset="71-77" id="DDI-PubMed.27245340.s1.e1" text="LCZ696" /><entity charOffset="87-98" id="DDI-PubMed.27245340.s1.e2" text="Angiotensin" /><pair ddi="false" e1="DDI-PubMed.27245340.s1.e0" e2="DDI-PubMed.27245340.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s1.e0" e2="DDI-PubMed.27245340.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s1.e0" e2="DDI-PubMed.27245340.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s1.e1" e2="DDI-PubMed.27245340.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s1.e1" e2="DDI-PubMed.27245340.s1.e2" /></sentence><sentence text="LCZ696 (sacubitril/valsartan), a novel angiotensin receptor neprilysin inhibitor has been recently approved for the treatment of patients with heart failure (HF) and reduced ejection fraction"><entity charOffset="8-18" id="DDI-PubMed.27245340.s2.e0" text="sacubitril" /><entity charOffset="19-28" id="DDI-PubMed.27245340.s2.e1" text="valsartan" /><entity charOffset="39-50" id="DDI-PubMed.27245340.s2.e2" text="angiotensin" /><pair ddi="false" e1="DDI-PubMed.27245340.s2.e0" e2="DDI-PubMed.27245340.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s2.e0" e2="DDI-PubMed.27245340.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s2.e0" e2="DDI-PubMed.27245340.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s2.e1" e2="DDI-PubMed.27245340.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s2.e1" e2="DDI-PubMed.27245340.s2.e2" /></sentence><sentence text=" As several HF patients are likely to use statins as co-medications, the potential for a pharmacokinetic drug-drug interaction between atorvastatin and LCZ696 was evaluated"><entity charOffset="135-147" id="DDI-PubMed.27245340.s3.e0" text="atorvastatin" /><entity charOffset="152-158" id="DDI-PubMed.27245340.s3.e1" text="LCZ696" /><pair ddi="false" e1="DDI-PubMed.27245340.s3.e0" e2="DDI-PubMed.27245340.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s3.e0" e2="DDI-PubMed.27245340.s3.e1" /></sentence><sentence text="" /><sentence text="This was an open-label, three-period, single-sequence study in 28 healthy Chinese male subjects wherein LCZ696 200 mg was administered twice daily for 5 days in period 1" /><sentence text=" Following a washout period, atorvastatin 80 mg was administered once daily for 4 days (period 2) and subsequently co-administered with LCZ696 200 mg for 5 days (period 3)" /><sentence text=" Serial plasma samples were collected to determine pharmacokinetic parameters of LCZ696 analytes (sacubitril, LBQ657, and valsartan) and atorvastatin and its metabolites"><entity charOffset="98-108" id="DDI-PubMed.27245340.s7.e0" text="sacubitril" /><entity charOffset="110-116" id="DDI-PubMed.27245340.s7.e1" text="LBQ657" /><entity charOffset="122-131" id="DDI-PubMed.27245340.s7.e2" text="valsartan" /><entity charOffset="137-149" id="DDI-PubMed.27245340.s7.e3" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e0" e2="DDI-PubMed.27245340.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e0" e2="DDI-PubMed.27245340.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e0" e2="DDI-PubMed.27245340.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e0" e2="DDI-PubMed.27245340.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e1" e2="DDI-PubMed.27245340.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e1" e2="DDI-PubMed.27245340.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e1" e2="DDI-PubMed.27245340.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e2" e2="DDI-PubMed.27245340.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s7.e2" e2="DDI-PubMed.27245340.s7.e3" /></sentence><sentence text="" /><sentence text="Atorvastatin co-administration had no effect on the pharmacokinetics of LBQ657, while the AUCτ,ss and C max,ss of sacubitril increased by 30 and 19 %, respectively, and the corresponding values for valsartan decreased by 19 and 9 %, respectively"><entity charOffset="0-12" id="DDI-PubMed.27245340.s9.e0" text="Atorvastatin" /><entity charOffset="198-207" id="DDI-PubMed.27245340.s9.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.27245340.s9.e0" e2="DDI-PubMed.27245340.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s9.e0" e2="DDI-PubMed.27245340.s9.e1" /></sentence><sentence text=" Co-administration with LCZ696 increased C max,ss of atorvastatin, o-hydroxyatorvastatin, and p-hydroxyatorvastatin by 74, 68, and 108 %, respectively, and the AUCτ,ss of corresponding analytes increased by 34, 22, and 26 %, respectively"><entity charOffset="53-65" id="DDI-PubMed.27245340.s10.e0" text="atorvastatin" /><entity charOffset="67-88" id="DDI-PubMed.27245340.s10.e1" text="o-hydroxyatorvastatin" /><entity charOffset="94-115" id="DDI-PubMed.27245340.s10.e2" text="p-hydroxyatorvastatin" /><pair ddi="false" e1="DDI-PubMed.27245340.s10.e0" e2="DDI-PubMed.27245340.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s10.e0" e2="DDI-PubMed.27245340.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s10.e0" e2="DDI-PubMed.27245340.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27245340.s10.e1" e2="DDI-PubMed.27245340.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27245340.s10.e1" e2="DDI-PubMed.27245340.s10.e2" /></sentence><sentence text="" /><sentence text="While atorvastatin had no significant impact on the pharmacokinetics of LCZ696 analytes upon co-administration, the C max of atorvastatin and its metabolites increased twofold, with a marginal increase in AUC (&lt;1"><entity charOffset="6-18" id="DDI-PubMed.27245340.s12.e0" text="atorvastatin" /><entity charOffset="125-137" id="DDI-PubMed.27245340.s12.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.27245340.s12.e0" e2="DDI-PubMed.27245340.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27245340.s12.e0" e2="DDI-PubMed.27245340.s12.e1" /></sentence><sentence text="3-fold)" /><sentence text=" Multiple-dose administration of LCZ696 200 mg twice daily and atorvastatin 80 mg once daily either alone or in combination was generally safe and well tolerated in healthy subjects" /><sentence text="" /></document>